About Englewood Hospital and Medical Center

News

2013 Press Releases

 

New Hope for Patients with Potentially Deadly Heart Condition

- Alternative Valve Replacement Technique Now Offered at Englewood Hospital and Medical Center-

(Englewood, NJ, February 6, 2013) – Patients diagnosed with a sometimes fatal heart condition called severe aortic stenosis (AS) now have access to a potentially life-saving valve replacement procedure at Englewood Hospital and Medical Center. The Medical Center’s award-winning cardiac team has recently performed the new transcatheter aortic valve replacement (TAVR) on its initial series of patients, with successful outcomes in all cases.

“Englewood Hospital is one of only a few in the state offering this groundbreaking interventional technique, which provides a much-needed alternative to patients who are too sick or frail to undergo traditional open heart surgery,” explained James Klein, MD, Chief of Cardiothoracic Surgery at Englewood Hospital.”

In the U.S. alone, more than half of the 250,000 patients diagnosed with severe AS will die within two years without treatment. TAVR is a potential lifeline to patients who qualify for this less invasive procedure.

“We are thrilled to be at the forefront of this new era in cardiac care,” said Richard Goldweit, MD, Chief of Interventional Cardiology at Englewood Hospital. “Englewood Hospital’s heart team is a model for the collaborative approach and was among the first in the region to combine the expertise of the nation’s best heart specialists in one convenient location for the benefit of the patient. Adding TAVR to our existing cardiac valve program not only aligns with our mission to provide the most advanced treatment available, but also allows us to help the patients who would likely not survive without the procedure.”

The Food and Drug Administration (FDA) recently expanded the approved use of the Edwards SAPIEN artificial heart replacement valve to include patients with a high risk of serious surgical complications or death, in addition to inoperable patients. It is the only approved TAVR therapy in the U.S. and could help thousands of patients live longer, fuller lives.

“The FDA’s approval gives us a brand new treatment option to offer a high risk group of patients who previously had little hope,” explained Adam Arnofsky, MD, Director of Cardiac Surgery Services at Englewood Hospital. “We are now able to replace the failing valve with the new valve through a very small puncture in the leg artery. This exciting technology is changing how we approach valvular heart disease for all of our patients.”

AS is the most commonly diagnosed heart valve condition, caused by a narrowing that prevents the flow of blood to the body from the heart. Symptoms include chest pain, fatigue, shortness of breath, heart palpitations and fainting. It forces the heart to work harder and weakens it over time, putting patients at increased risk for heart failure.

TAVR offers new hope to patients with severe AS and is being hailed as a game changer by Englewood Hospital’s heart team. The Medical Center’s state-of-the-art Hybrid Operating Room provides the necessary environment, advanced technology and equipment needed to perform this innovative procedure. Englewood Hospital’s multidisciplinary team approach is a critical component to the success of each surgery, with the cardiothoracic surgeon and interventional cardiologist working in partnership to achieve the best possible outcome for every patient.

“We are proud to be among a select group of hospitals in the state to offer this advancement in the treatment of severe aortic stenosis,” said Joseph De Gregorio, MD, Chief of Invasive Cardiology at Englewood Hospital. “We look forward to helping to restore the quality of life for our patients and their loved ones in the years to come.”

 
About Englewood Hospital and Medical Center
 
Englewood Hospital and Medical Center provides the highest level of compassionate, patient care and safety through a broad range of advanced clinical programs, treatments and diagnostic services. It is renowned for its bloodless medicine and surgery program, cardiac and vascular programs and its leadership in breast care, oncology and joint replacement services. Through its affiliation with the Mount Sinai School of Medicine and the Mount Sinai Consortium for Graduate Medical Education, this acute-care and community teaching hospital trains medical residents in many disciplines, including internal medicine, critical care medicine, surgery, pediatrics, podiatry, and pathology.   Additionally, many members of Englewood Hospital’s medical staff serve as faculty at Mount Sinai. Englewood Hospital has earned numerous accreditations from the Joint Commission and other organizations and is among the four percent of hospitals nationwide honored with the prestigious Magnet nursing award, a distinction that has been earned three times by its nursing staff.